Roles of LuxR-family regulators in the biosynthesis of secondary metabolites in Actinobacteria.

World J Microbiol Biotechnol

Institute of Biopharmaceuticals, Taizhou University, 318000, Taizhou, China.

Published: October 2022

Actinobacteria are well-known Gram-positive bacteria that produce approximately two-thirds of microbial bioactive natural products (NPs) through secondary metabolism. Usually, genes involved in the biosynthesis of NPs in actinobacteria are clustered, and their expression is regulated by an elaborate and stringent regulatory network formed by diverse regulators. These regulators can be classified into more than 50 superfamilies/families according to conserved amino acid sequences and biological functions. Among them, LuxR family regulators, which are widely distributed in microorganisms and feature an HTH_LUXR domain (PFAM00196, SMART00421), play key roles in quorum sensing (QS), bioluminescence, virulence and secondary metabolism. In this mini-review, we focus on their roles in regulating NP production in actinobacteria. First, the domain architecture and classification of LuxR proteins are summarized on the basis of their size and biological function diversity. Second, the landscape of the roles and action mechanism of LuxR regulators involved in NP production in actinobacteria is presented in detail. Finally, the application of LuxR is described from two perspectives: enhancement of NP production and discovery of novel NPs by engineering LuxR. This mini-review will help us comprehensively understand the role of LuxR in actinobacteria and promote the future application of LuxR family regulators in synthetic biology.

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11274-022-03414-1DOI Listing

Publication Analysis

Top Keywords

secondary metabolism
8
luxr family
8
family regulators
8
production actinobacteria
8
application luxr
8
luxr
7
regulators
6
actinobacteria
6
roles
4
roles luxr-family
4

Similar Publications

Following myocardial infarction (MI), the accumulation of CD86-positive macrophages in the ischemic injury zone leads to secondary myocardial damage. Precise pharmacological intervention targeting this process remains challenging. This study engineered a nanotherapeutic delivery system with CD86-positive macrophage-specific targeting and ultrasound-responsive release capabilities.

View Article and Find Full Text PDF

Medicinal plants often harbour various endophytic actinomycetia, which are well known for their potent antimicrobial properties and plant growth-promoting traits. In this study, we isolated an endophytic actinomycetia, A13, from the leaves of tea clone P312 from the MEG Tea Estate, Meghalaya, India. The isolate A13 was identified as Streptomyces sp.

View Article and Find Full Text PDF

Elimination of oral foci of infection might lead to clinical improvement of Graves' orbitopathy.

Graefes Arch Clin Exp Ophthalmol

January 2025

Department of Endocrinology, Metabolism and Internal Medicine, Poznan University of Medical Sciences, Przybyszewskiego 49, 60-355, Poznan, Poland.

Purpose: Graves' disease (GD) and Graves' orbitopathy (GO) are multifactorial disorders with links to the gut microbiome and autoimmunity. It is observed that patients with GD exhibit altered gut microbiome diversity. However, little is known about the role of oral microbiota in GD and GO.

View Article and Find Full Text PDF

Background: Alzheimer's disease (AD) is an age-related neurodegenerative disorder affecting nearly 50 million individuals worldwide. Besides aging, various comorbidities can increase the risk of AD, such as asthma. However, the molecular mechanism(s) underlying this asthma-associated AD exacerbation is unknown.

View Article and Find Full Text PDF

Basic Science and Pathogenesis.

Alzheimers Dement

December 2024

Indiana University, Indianapolis, IN, USA.

Background: Preclinical testing in animal models is a critical component of the drug discovery process. Over the past three decades hundreds of interventions have demonstrated preclinical efficacy for ameliorating cognitive impairments in animal models; however, none have translated to efficacy in Alzheimer's disease (AD) clinical trials. This lack of translation suggests that there are issues with the animal models employed, the preclinical assays, and poor scientific rigor and reproducibility during execution.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!